Enhancement of morphine antinociception by ibogaine and noribogaine in morphine-tolerant mice.
S Sunder Sharma, Hemendra N. Bhargava
Pharmacology November 1, 1998 DOI: 10.1159/000028246 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Preclinical experimental study Peer reviewed |
|---|---|
| Population | Male Swiss-Webster mice |
| Interventions | Ibogaine Noribogaine Morphine |
| Dose | morphine 10 mg/kg, s.c.; morphine pellet 25 mg |
| Duration | 3-day morphine pellet implantation |
| Topics | Ibogaine |
| Keywords | Opioid tolerance Pain management Pharmacology |
| Citations | 17 |
| Key findings | Ibogaine and noribogaine dose-dependently enhanced morphine antinociception in morphine-tolerant but not in morphine-naive mice. |
Abstract
The effects of ibogaine, an alkaloid isolated form the bark of the African shrub, Tabernathe iboga, and noribogaine, a metabolite of ibogaine, on morphine antinociception were determined in male Swiss-Webster mice. Mice were rendered tolerant to morphine by implanting them with a pellet containing 25 mg of morphine base for 3 days. Placebo pellet-implanted mice served as controls. The antinociception of morphine (10 mg/kg, s.c.) was determined alone or in combination with an appropriate dose of ibogaine or noribogaine. Tolerance to morphine developed as a result of morphine pellet implantation as evidenced by decreased antinociceptive response to morphine. Both ibogaine and noribogaine dose-dependently enhanced morphine antinociception in morphine-tolerant but not in morphine-naive mice. It is concluded that ibogaine and noribogaine enhance morphine antinociception in morphine-tolerant mice.